Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) insider Akshay Vaishnaw sold 23,708 shares of the business’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $125.00, for a total transaction of $2,963,500.00. Following the transaction, the insider now directly owns 30,923 shares in the company, valued at $3,865,375. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shares of Alnylam Pharmaceuticals stock opened at $133.99 on Thursday. The stock has a market cap of $14.66 billion, a price-to-earnings ratio of -16.46 and a beta of 2.47. The firm’s 50-day moving average is $118.69 and its 200 day moving average is $97.98. Alnylam Pharmaceuticals, Inc. has a 1 year low of $65.81 and a 1 year high of $134.51. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.38 and a quick ratio of 5.22.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported ($2.47) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.25) by ($0.22). The firm had revenue of $71.70 million during the quarter, compared to the consensus estimate of $71.45 million. Alnylam Pharmaceuticals had a negative return on equity of 54.13% and a negative net margin of 403.24%. The business’s revenue for the quarter was up 241.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.82) EPS. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.14 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the stock. Amundi Pioneer Asset Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 12.6% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 149,659 shares of the biopharmaceutical company’s stock worth $13,986,000 after acquiring an additional 16,733 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 107.7% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 837 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 434 shares during the period. BlackRock Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 1.7% during the 2nd quarter. BlackRock Inc. now owns 6,537,253 shares of the biopharmaceutical company’s stock worth $474,340,000 after acquiring an additional 109,126 shares during the period. City Holding Co. bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $30,000. Finally, DNB Asset Management AS bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $913,000. Institutional investors own 95.75% of the company’s stock.
ALNY has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $176.00 target price (up from $159.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, December 18th. Zacks Investment Research downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $98.00 target price on the stock. in a research report on Tuesday, November 19th. Cowen reaffirmed a “buy” rating and issued a $154.00 target price on shares of Alnylam Pharmaceuticals in a research report on Sunday. Morgan Stanley reduced their target price on shares of Alnylam Pharmaceuticals from $150.00 to $148.00 and set an “overweight” rating on the stock in a research report on Friday, February 7th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $124.17.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Featured Story: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.